# OnCo record monarch-3 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/monarch-3/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "monarch-3", "NCT02246621" ;
  schema:name "MONARCH 3"@en ;
  schema:description "Abemaciclib roughly doubled the time to progression when added to an aromatase inhibitor; the survival gain of about 13 months narrowly missed statistical significance."@en ;
  schema:url <https://onco.cc/trials/monarch-3/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02246621> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2014-11-06" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:technologies <https://onco.cc/technologies/cdk46-inhibitor/> ;
  onco:targets <https://onco.cc/targets/cdk4-6/> ;
  onco:drugs <https://onco.cc/drugs/abemaciclib/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> ;
  onco:people <https://onco.cc/people/matthew-goetz/> .